C. Difficile Infections

The COVID-19 pandemic underscored challenges in the prevention and treatment of health care-associated infections.

Use of the investigational microbiome therapeutic SER-109 resulted in rapid and steady improvement in disease-specific quality of life for patients with recurrent Clostridioides difficile infection, according to data in JAMA Network Open.

Bezlotoxumab and fecal microbiota transplantation were similarly effective at preventing both early and late recurrent Clostridioides difficile infection, according to a study published in Open Forum Infectious Diseases.

WASHINGTON — Nearly three out of every four patients with Clostridioides difficile infection being treated with ridinilazole had a sustained clinical response, according to data presented at IDWeek.

In this video, Jessica R. Allegretti, MD, MPH, discussed a presentation from the ACG Annual Scientific Meeting that provided an overview of microbiome therapeutics  currently under investigation for Clostridioides difficile infection.

Jessica R. Allegretti, MD, MPH, spoke with Healio about a study demonstrating the efficacy of SER-109 in preventing recurrent Clostridioides difficile infection, including in patients using acid-suppressing medications.

In this video, Jessica R. Allegretti, MD, MPH, discussed findings from the PRISM3 trial evaluating an investigational therapeutic for the prevention of recurrent Clostridioides difficile infection.

Research presented at the World Microbe Forum virtual meeting analyzed U.S. case counts and deaths during the first 3 months of the pandemic and identified public health approaches that reduced COVID-19-related deaths.